Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home
  • Log in
  • My Cart

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
Inner Workings

Inner Workings: Tyrosine kinases, their discovery and impact

Jessica Marshall

See allHide authors and affiliations

PNAS June 30, 2015 112 (26) 7886-7887; https://doi.org/10.1073/pnas.1510492112
Jessica Marshall
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

While working in his laboratory at the Salk Institute in 1979, Tony Hunter took a shortcut. Hunter decided not to make up fresh buffer for his electrophoresis run. That decision would alter his career, significantly influence the field of cancer biology, and ultimately lead to new cancer treatments.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

The discovery of tyrosine kinases paved the way for the cancer drug Gleevec. Here a human Abl tyrosine kinase domain is depicted in complex with Gleevec. Image courtesy of Shutterstock/bitsite.

Hunter was studying Rous sarcoma virus, the first known cancer-causing virus, reported in 1911 by Peyton Rous, who showed it caused cancer in chickens. Rous’s discovery, which earned him the Nobel Prize in 1966, would eventually spur the search for other cancer-causing viruses, provide cancer researchers a way to study cancer at a molecular level, and lead to the discovery of the first oncogenes (1).

Hunter wanted to understand the enzyme responsible for triggering tumor growth by the virus, which had already been identified as a protein kinase: an enzyme that adds a phosphate to another protein (2). The buffer’s pH had fallen slightly as it sat on the bench, which caused two amino acids—phosphothreonine and phosphotyrosine—to separate from each other on the electrophoresis plate, when normally they would have run together. This separation revealed that the target for the cancer-causing protein kinase was tyrosine.

It was the first report of a tyrosine kinase (3), a class of proteins that would prove to be crucial in cell signaling. Hunter and his colleague, Bartholomew Sefton, had expected to find a serine or threonine kinase, which had been identified previously. Instead, it was tyrosine. “It was a big deal because it wasn’t what everyone expected,” says cancer biologist Owen Witte of the University of California, Los Angeles.

At the same time, Witte and his colleagues reported that the cancer-causing Abelson virus, which acts in mice, worked via another protein that added a phosphorous to tyrosine. But, this occurred through self-phosphorylation (4).

Tyrosine kinases act as a signal relay that control many cellular pathways, including cell growth. When the kinases become mutated in cancer, cell division spirals out of control. This understanding ultimately led to the development of a whole new class of cancer drugs known as tyrosine kinase inhibitors.

“People immediately realized that many kinases may be tyrosine kinases,” says Stanley Lipkowitz of the National Cancer Institute. Researchers began looking for other tyrosine kinases, and they found them everywhere: in other types of cancer and in central cell-signaling pathways unrelated to cancer. A flurry of papers came out within just a few months of the first report.

“It went from an interesting curiosity of a mouse virus and a chicken virus, to ‘every mammalian cell has this activity,’” Witte says. As researchers continued to look for tyrosine kinases in subsequent years, they found that not only mammalian cells, but nearly all eukaryotes, aside from yeast, use tyrosine kinases as part of their cellular signaling machinery, he says.

Knowing that tyrosine kinases could be oncogenes suggested they were possible cancer treatment targets. But studies of the human genome revealed 500 protein kinases, and many researchers initially feared it would be impossible to inhibit the activity of an oncogenic tyrosine kinase without inhibiting all of them, says Brian Druker, an oncologist and the director of the Knight Cancer Institute at Oregon Health & Science University. “There wasn’t a huge amount of enthusiasm, and companies weren’t jumping in to develop kinase inhibitors,” Druker says.

Nevertheless, work by Druker and the pharmaceutical company Ciba-Geigy, now Novartis, ultimately led to the Food and Drug Administration approval of imatinib, popularly known as Gleevec, in 2001. The first tyrosine kinase inhibitor, Gleevec effectively treats chronic myelogenous leukemia and several other cancers driven by activated tyrosine kinases. Before Gleevec, roughly half of chronic myelogenous leukemia patients lived five years, Druker notes. Now 90% do.

“It really stops that kind of leukemia in its tracks,” says Witte. “In the early phase of the disease, it’s as close to a cure as you’re going to imagine.”

Gleevec was the first, but now more than 20 approved cancer drugs are tyrosine kinase inhibitors, Hunter says. Even more are in clinical trials, not only for cancer, but for autoimmune disorders and other illnesses.

“We’re going to learn so much more about the role of kinases in various diseases over the next 10 to 20 years, and this will lead to the development of specific inhibitors to treat those diseases,” says Druker. Cancers also can become resistant to tyrosine kinase inhibitors over time. “We need to stay a step ahead of [cancer],” he adds. “We need multiple generations of inhibitors.”

References

  1. ↵
    1. Weiss RA,
    2. Vogt PK
    (2011) 100 years of Rous sarcoma virus. J Exp Med 208(12):2351–2355
    .
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Collett MS,
    2. Erikson RL
    (1978) Protein kinase activity associated with the avian sarcoma virus src gene product. Proc Natl Acad Sci USA 75(4):2021–2024
    .
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Hunter T,
    2. Sefton BM
    (1980) Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci USA 77(3):1311–1315
    .
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Witte ON,
    2. Dasgupta A,
    3. Baltimore D
    (1980) Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature 283(5750):826–831
    .
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Article Alerts
Email Article

Thank you for your interest in spreading the word on PNAS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Inner Workings: Tyrosine kinases, their discovery and impact
(Your Name) has sent you a message from PNAS
(Your Name) thought you would like to see the PNAS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Discovery and impact of tyrosine kinase
Jessica Marshall
Proceedings of the National Academy of Sciences Jun 2015, 112 (26) 7886-7887; DOI: 10.1073/pnas.1510492112

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Discovery and impact of tyrosine kinase
Jessica Marshall
Proceedings of the National Academy of Sciences Jun 2015, 112 (26) 7886-7887; DOI: 10.1073/pnas.1510492112
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Mendeley logo Mendeley

Related Article

  • Discovering the first tyrosine kinase
    - Jun 30, 2015
Proceedings of the National Academy of Sciences: 112 (26)
Table of Contents

Submit

Sign up for Article Alerts

Jump to section

  • Article
    • References
  • Figures & SI
  • Info & Metrics
  • PDF

You May Also be Interested in

Reflection of clouds in the still waters of Mono Lake in California.
Inner Workings: Making headway with the mysteries of life’s origins
Recent experiments and simulations are starting to answer some fundamental questions about how life came to be.
Image credit: Shutterstock/Radoslaw Lecyk.
Depiction of the sun's heliosphere with Voyager spacecraft at its edge.
News Feature: Voyager still breaking barriers decades after launch
Launched in 1977, Voyagers 1 and 2 are still helping to resolve past controversies even as they help spark a new one: the true shape of the heliosphere.
Image credit: NASA/JPL-Caltech.
Drop of water creates splash in a puddle.
Journal Club: Heavy water tastes sweeter
Heavy hydrogen makes heavy water more dense and raises its boiling point. It also appears to affect another characteristic long rumored: taste.
Image credit: Shutterstock/sl_photo.
Mouse fibroblast cells. Electron bifurcation reactions keep mammalian cells alive.
Exploring electron bifurcation
Jonathon Yuly, David Beratan, and Peng Zhang investigate how electron bifurcation reactions work.
Listen
Past PodcastsSubscribe
Panda bear hanging in a tree
How horse manure helps giant pandas tolerate cold
A study finds that giant pandas roll in horse manure to increase their cold tolerance.
Image credit: Fuwen Wei.

Similar Articles

Site Logo
Powered by HighWire
  • Submit Manuscript
  • Twitter
  • Facebook
  • RSS Feeds
  • Email Alerts

Articles

  • Current Issue
  • Special Feature Articles – Most Recent
  • List of Issues

PNAS Portals

  • Anthropology
  • Chemistry
  • Classics
  • Front Matter
  • Physics
  • Sustainability Science
  • Teaching Resources

Information

  • Authors
  • Editorial Board
  • Reviewers
  • Subscribers
  • Librarians
  • Press
  • Cozzarelli Prize
  • Site Map
  • PNAS Updates
  • FAQs
  • Accessibility Statement
  • Rights & Permissions
  • About
  • Contact

Feedback    Privacy/Legal

Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490